These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 27835591

  • 21. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
    Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, Yan T.
    PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
    [Abstract] [Full Text] [Related]

  • 22. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 23. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

  • 24. Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells.
    Yin Y, Sun H, Xu J, Xiao F, Wang H, Yang Y, Ren H, Wu CT, Gao C, Wang L.
    Leuk Lymphoma; 2015 Jun; 56(6):1813-20. PubMed ID: 25146433
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 28. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J.
    Mol Cancer; 2010 May 19; 9():112. PubMed ID: 20482842
    [Abstract] [Full Text] [Related]

  • 29. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R.
    Cancer Biol Ther; 2012 Nov 19; 13(13):1244-54. PubMed ID: 22895079
    [Abstract] [Full Text] [Related]

  • 30. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H, Gajulapalli SR, Lernoux M, Lee JY, Mazumder A, Gérard D, Seidel C, Hahn H, Christov C, Dicato M, Kirsch G, Han BW, Schnekenburger M, Diederich M.
    Pharmacol Res; 2020 Oct 19; 160():105058. PubMed ID: 32619722
    [Abstract] [Full Text] [Related]

  • 31. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 32. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.
    Clin Cancer Res; 2014 Jan 01; 20(1):151-63. PubMed ID: 24334603
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.
    Oncotarget; 2016 Apr 05; 7(14):18204-18. PubMed ID: 26919095
    [Abstract] [Full Text] [Related]

  • 34. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.
    Oncotarget; 2012 Dec 05; 3(12):1557-65. PubMed ID: 23238683
    [Abstract] [Full Text] [Related]

  • 35. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R.
    Blood; 2013 Mar 07; 121(10):1824-38. PubMed ID: 23299311
    [Abstract] [Full Text] [Related]

  • 36. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW.
    Korean J Intern Med; 2016 Mar 07; 31(2):357-66. PubMed ID: 26874514
    [Abstract] [Full Text] [Related]

  • 37. Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
    Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S.
    Cancer Sci; 2018 Jan 07; 109(1):121-131. PubMed ID: 29121435
    [Abstract] [Full Text] [Related]

  • 38. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 39. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
    Zhou Z, Liu T, Zhang J.
    Biochem Biophys Res Commun; 2019 Dec 10; 520(3):560-565. PubMed ID: 31615652
    [Abstract] [Full Text] [Related]

  • 40. Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
    Liu Z, Zheng W, Liu Y, Zhou B, Zhang Y, Wang F.
    Exp Cell Res; 2021 Aug 15; 405(2):112708. PubMed ID: 34157313
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.